RETLIRA is a powerful triple-action peptide therapy containing 30mg of Retatrutide, a new-generation weight loss compound targeting: GLP-1 receptors reduces appetite and stabilizes blood sugar GIP receptors improves insulin sensitivity Glucagon receptors boosts fat burning and metabolism RETLIRA mimics three key metabolic hormones in one weekly injection, outperforming older GLP-1 options like Semaglutide and Tirzepatide
Many North Americans struggle with weight loss, whether the scale just wont budge or fluctuates up and down like a yo-yo
Consistent dosing
Week 2+ Your new normal
These drugs offer substantial potential health benefits, but the combination of intense demand, new uses, and high prices for these treatments is likely to place tremendous pressure on Medicare spending, Part D plan costs, and premiums for Part D coverage.
Ipamorelin, by contrast, belongs to the class of growth hormone secretagogues (GHS), functioning as a ghrelin receptor agonist